Esra Esim Buyukbayrak
Esra Esim Buyukbayrak has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Merve Kara
Beykoz State Hospital, Istanbul, Turkey
3 shared publications - Münip Akalın
Department of Perinatology Marmara University Pendik Training and Research Hospital Istanbul Turkey
3 shared publications - Bulent Kars
Kartal Dr. Lütfi Kırdar Training and Resarch Hospital, Clinics of Obstetrics and Gynecology, İstanbul, Turkey
2 shared publications - Cagdas Nurettin Emeklioglu
UNIVERSITY OF HEALTH SCIENCES, İSTANBUL OKMEYDANI HEALTH RESEARCH CENTER, DEPARTMENT OF SURGICAL MEDICAL SCIENCES, DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY
2 shared publications - Ayşe Yasemin KARAGEYİM KARŞIDAĞ
Kirklareli University
1 shared publication Bahar Ergen
Dr. Lütfi Kırdar Kartal Education and Research Hospital
1 shared publication
Latest Publications
- Open Access
- 3 July 2026
- Published by Elsevier in SSRN Electronic Journal
Implementation of the Updated 2025 mWHO 2.0 Classification and Perinatal Outcomes in Cardiac Pregnancies: A Tertiary Center Experience
BackgroundTo implement the newly updated 2025 European Society of Cardiology (ESC) modified World Health Organization (mWHO) 2.0 classification in a cohort of pregnant women with cardiovascular disease, and to evaluate the clinical impact of disease acuity, referral timing, and specialized maternal-fetal medicine (MFM) surveillance intensity on granular obstetric and neonatal outcomes.MethodsThis retrospective, observational cohort study analyzed 82 maternal-fetal dyads managed at a tertiary center. Patients were stratified into a Low-Risk Group (mWHO 2.0 Class I–II; n=40) and a Moderate-to-Extreme High-Risk Group (Classes II–III,III, and IV; n=42). Surveillance intensity was measured by referral timing and total MFM visits. Multivariate logistic and linear regression models were constructed to identify independent predictors of adverse perinatal endpoints.ResultsValvular disease predominated (54.9%). A paradoxical referral pattern emerged, with 71.4% of high-risk versus 50.0% of low-risk patients referred late (≥14 weeks; p=0.047). In multivariate logistic regression, high-risk mWHO 2.0 status was the sole independent predictor for preterm birth (aOR: 4.292, p=0.007) and NICU admission (aOR: 2.662, p=0.045). Multiple linear regression showed neonatal birth weight was uniquely governed by gestational age (p<0.001) and maternal age (p=0.014), rather than mWHO tier (p=0.675). The high-risk group had a 90.2% Cesarean rate (p=0.040).ConclusionThe 2025 mWHO 2.0 tier robustly predicts neonatal morbidity, which is iatrogenically driven by indicated preterm deliveries to prevent maternal failure. Systemic adjustments are required to improve late referral patterns and optimize early multidisciplinary care.
- 3 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImplementation of the Updated 2025 mWHO 2.0 Classification and Perinatal Outcomes in Cardiac Pregnancies: A Tertiary Center Experience
BackgroundTo implement the newly updated 2025 European Society of Cardiology (ESC) modified World Health Organization (mWHO) 2.0 classification in a cohort of pregnant women with cardiovascular disease, and to evaluate the clinical impact of disease acuity, referral timing, and specialized maternal-fetal medicine (MFM) surveillance intensity on granular obstetric and neonatal outcomes.MethodsThis retrospective, observational cohort study analyzed 82 maternal-fetal dyads managed at a tertiary center. Patients were stratified into a Low-Risk Group (mWHO 2.0 Class I–II; n=40) and a Moderate-to-Extreme High-Risk Group (Classes II–III,III, and IV; n=42). Surveillance intensity was measured by referral timing and total MFM visits. Multivariate logistic and linear regression models were constructed to identify independent predictors of adverse perinatal endpoints.ResultsValvular disease predominated (54.9%). A paradoxical referral pattern emerged, with 71.4% of high-risk versus 50.0% of low-risk patients referred late (≥14 weeks; p=0.047). In multivariate logistic regression, high-risk mWHO 2.0 status was the sole independent predictor for preterm birth (aOR: 4.292, p=0.007) and NICU admission (aOR: 2.662, p=0.045). Multiple linear regression showed neonatal birth weight was uniquely governed by gestational age (p<0.001) and maternal age (p=0.014), rather than mWHO tier (p=0.675). The high-risk group had a 90.2% Cesarean rate (p=0.040).ConclusionThe 2025 mWHO 2.0 tier robustly predicts neonatal morbidity, which is iatrogenically driven by indicated preterm deliveries to prevent maternal failure. Systemic adjustments are required to improve late referral patterns and optimize early multidisciplinary care.
- Open Access
- 19 July 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 53 (9) , 2081-2087
Diagnostic Performance of Standardized First Trimester Fetal Echocardiography for the Detection of Congenital Heart Defects
Purpose: To determine the diagnostic accuracy of standardized first trimester (11 +0 –14 +0 weeks of gestation) fetal echocardiography (FE) for the detection of congenital heart defects (CHDs). Methods: Pregnant women who underwent FE in the first trimester at a tertiary center between November 2021 and December 2022 were included in this retrospective study. In the first trimester, FE; heart position with cardiac axis, heart rhythm, four‐chamber view with two distinct ventricles, left ventricular outflow tract view, and three vessel trachea view were evaluated. CHDs were grouped as mild (do not require treatment or can be easily treated without affecting the child in the long term) and severe (expected to require surgery or cardiac catheterization, may affect the child in the long term) according to their severity. Results: A total of 311 pregnant women were included in the study, and 22 (7.1%) fetuses were diagnosed with CHDs. Of the 22 fetuses, 6 (27.3%) had severe CHDs, and 16 (72.7%) had mild CHDs. All severe CHDs were correctly diagnosed on first trimester FE. The sensitivity of first trimester FE for overall CHDs was 54.5%, and specificity was 100%. The performance of first trimester FE in the diagnosis of severe CHDs was excellent, with 100% sensitivity and 100% specificity. Conclusion: First trimester FE has high detection rates for early diagnosis of severe CHDs. Standardized first trimester FE may allow early diagnosis of fetuses with CHDs and contribute to the appropriate management of these pregnancies.
- 19 July 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 53 (9) , 2081-2087
Open AccessDiagnostic Performance of Standardized First Trimester Fetal Echocardiography for the Detection of Congenital Heart Defects
Purpose: To determine the diagnostic accuracy of standardized first trimester (11 +0 –14 +0 weeks of gestation) fetal echocardiography (FE) for the detection of congenital heart defects (CHDs). Methods: Pregnant women who underwent FE in the first trimester at a tertiary center between November 2021 and December 2022 were included in this retrospective study. In the first trimester, FE; heart position with cardiac axis, heart rhythm, four‐chamber view with two distinct ventricles, left ventricular outflow tract view, and three vessel trachea view were evaluated. CHDs were grouped as mild (do not require treatment or can be easily treated without affecting the child in the long term) and severe (expected to require surgery or cardiac catheterization, may affect the child in the long term) according to their severity. Results: A total of 311 pregnant women were included in the study, and 22 (7.1%) fetuses were diagnosed with CHDs. Of the 22 fetuses, 6 (27.3%) had severe CHDs, and 16 (72.7%) had mild CHDs. All severe CHDs were correctly diagnosed on first trimester FE. The sensitivity of first trimester FE for overall CHDs was 54.5%, and specificity was 100%. The performance of first trimester FE in the diagnosis of severe CHDs was excellent, with 100% sensitivity and 100% specificity. Conclusion: First trimester FE has high detection rates for early diagnosis of severe CHDs. Standardized first trimester FE may allow early diagnosis of fetuses with CHDs and contribute to the appropriate management of these pregnancies.
- 9 May 2009
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 106 (3) , 250-253
Vaginal versus sublingual misoprostol for second-trimester pregnancy termination and effect on Doppler measurements
To compare the efficacy of vaginal versus sublingual misoprostol for second-trimester pregnancy termination, and to evaluate the effect on the blood flow of the uterine and umbilical arteries. Forty-nine patients were randomized to receive either 200 microg of vaginal misoprostol every 6 hours or 200 microg of misoprostol sublingually every 6 hours. Doppler velocimetry studies were assessed immediately before and 60 minutes after the administration of the first dose. Standard descriptive calculations, Mann-Whitney U, Wilcoxon, and chi(2) tests were performed. The mean interval between induction and onset of active labor, induction and delivery, and the duration of oxytocin administration were significantly shorter in the sublingual misoprostol group. Both routes of administration increased the Doppler indices for the uterine arteries; however, misoprostol via the sublingual route did not affect the umbilical arteries. Sublingual administration of misoprostol for second-trimester medical abortion results in a higher success rate and does not affect umbilical blood flow.
- 9 May 2009
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 106 (3) , 250-253
Vaginal versus sublingual misoprostol for second-trimester pregnancy termination and effect on Doppler measurements
To compare the efficacy of vaginal versus sublingual misoprostol for second-trimester pregnancy termination, and to evaluate the effect on the blood flow of the uterine and umbilical arteries. Forty-nine patients were randomized to receive either 200 microg of vaginal misoprostol every 6 hours or 200 microg of misoprostol sublingually every 6 hours. Doppler velocimetry studies were assessed immediately before and 60 minutes after the administration of the first dose. Standard descriptive calculations, Mann-Whitney U, Wilcoxon, and chi(2) tests were performed. The mean interval between induction and onset of active labor, induction and delivery, and the duration of oxytocin administration were significantly shorter in the sublingual misoprostol group. Both routes of administration increased the Doppler indices for the uterine arteries; however, misoprostol via the sublingual route did not affect the umbilical arteries. Sublingual administration of misoprostol for second-trimester medical abortion results in a higher success rate and does not affect umbilical blood flow.
- 12 January 2008
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 278 (2) , 161-163
Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report
Pregnancy and cancer is a complex situation. The coincidence of chronic myelogeneous leukemia (CML) and pregnancy is an uncommon event, in part because CML occurs mostly in older age groups. The management of CML during pregnancy is a difficult problem because of the potential effects of the therapy on the mother and fetus. Imatinib is a relatively new drug in this era and it induces dramatic hematologic and cytogenetic responses in CML but it is not recommended for use during pregnancy or if the patient plans to conceive. In the literature there are very few reports of outcome of pregnancy conceived while on imatinib. In this report, we describe a successful pregnancy and labor under treatment of imatinib in a patient who was diagnosed with CML at the beginning of her pregnancy.
- 12 January 2008
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 278 (2) , 161-163
Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report
Pregnancy and cancer is a complex situation. The coincidence of chronic myelogeneous leukemia (CML) and pregnancy is an uncommon event, in part because CML occurs mostly in older age groups. The management of CML during pregnancy is a difficult problem because of the potential effects of the therapy on the mother and fetus. Imatinib is a relatively new drug in this era and it induces dramatic hematologic and cytogenetic responses in CML but it is not recommended for use during pregnancy or if the patient plans to conceive. In the literature there are very few reports of outcome of pregnancy conceived while on imatinib. In this report, we describe a successful pregnancy and labor under treatment of imatinib in a patient who was diagnosed with CML at the beginning of her pregnancy.